|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPL10A |
Gene summary for RPL10A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPL10A | Gene ID | 4736 |
| Gene name | ribosomal protein L10a | |
| Gene Alias | CSA19 | |
| Cytomap | 6p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0000470 | UniProtAcc | P62906 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4736 | RPL10A | CA_HPV_1 | Human | Cervix | CC | 8.13e-08 | -2.90e-01 | 0.0264 |
| 4736 | RPL10A | CA_HPV_2 | Human | Cervix | CC | 3.90e-23 | -3.50e-01 | 0.0391 |
| 4736 | RPL10A | CA_HPV_3 | Human | Cervix | CC | 2.72e-02 | 1.31e-01 | 0.0414 |
| 4736 | RPL10A | N_HPV_2 | Human | Cervix | N_HPV | 2.30e-02 | -9.41e-02 | -0.0131 |
| 4736 | RPL10A | CCI_1 | Human | Cervix | CC | 1.89e-47 | -1.66e+00 | 0.528 |
| 4736 | RPL10A | CCI_2 | Human | Cervix | CC | 7.76e-35 | -1.23e+00 | 0.5249 |
| 4736 | RPL10A | CCI_3 | Human | Cervix | CC | 1.38e-56 | -1.65e+00 | 0.516 |
| 4736 | RPL10A | CCII_1 | Human | Cervix | CC | 9.65e-80 | -1.80e+00 | 0.3249 |
| 4736 | RPL10A | Tumor | Human | Cervix | CC | 2.94e-36 | -3.81e-01 | 0.1241 |
| 4736 | RPL10A | sample1 | Human | Cervix | CC | 3.16e-03 | -2.24e-01 | 0.0959 |
| 4736 | RPL10A | sample3 | Human | Cervix | CC | 1.39e-63 | -4.69e-01 | 0.1387 |
| 4736 | RPL10A | H2 | Human | Cervix | HSIL_HPV | 8.10e-28 | -4.40e-01 | 0.0632 |
| 4736 | RPL10A | L1 | Human | Cervix | CC | 2.44e-02 | -2.33e-01 | 0.0802 |
| 4736 | RPL10A | T1 | Human | Cervix | CC | 5.01e-25 | -3.89e-01 | 0.0918 |
| 4736 | RPL10A | T3 | Human | Cervix | CC | 5.01e-70 | -4.93e-01 | 0.1389 |
| 4736 | RPL10A | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.44e-119 | 2.79e+00 | 0.0155 |
| 4736 | RPL10A | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.06e-48 | 2.88e+00 | -0.1808 |
| 4736 | RPL10A | HTA11_2951_2000001011 | Human | Colorectum | AD | 2.01e-37 | 3.20e+00 | 0.0216 |
| 4736 | RPL10A | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.19e-64 | 3.06e+00 | -0.0811 |
| 4736 | RPL10A | HTA11_78_2000001011 | Human | Colorectum | AD | 1.93e-55 | 2.18e+00 | -0.1088 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
| GO:004227310 | Cervix | CC | ribosomal large subunit biogenesis | 26/2311 | 72/18723 | 1.87e-07 | 8.48e-06 | 26 |
| GO:002261310 | Cervix | CC | ribonucleoprotein complex biogenesis | 88/2311 | 463/18723 | 2.11e-05 | 3.82e-04 | 88 |
| GO:004225410 | Cervix | CC | ribosome biogenesis | 62/2311 | 299/18723 | 2.48e-05 | 4.27e-04 | 62 |
| GO:00973059 | Cervix | CC | response to alcohol | 46/2311 | 253/18723 | 4.40e-03 | 2.69e-02 | 46 |
| GO:00160727 | Cervix | CC | rRNA metabolic process | 42/2311 | 236/18723 | 9.12e-03 | 4.60e-02 | 42 |
| GO:000218115 | Cervix | HSIL_HPV | cytoplasmic translation | 86/737 | 148/18723 | 3.97e-82 | 1.91e-78 | 86 |
| GO:002261315 | Cervix | HSIL_HPV | ribonucleoprotein complex biogenesis | 52/737 | 463/18723 | 9.85e-12 | 6.81e-09 | 52 |
| GO:004225415 | Cervix | HSIL_HPV | ribosome biogenesis | 40/737 | 299/18723 | 1.25e-11 | 6.81e-09 | 40 |
| GO:004227315 | Cervix | HSIL_HPV | ribosomal large subunit biogenesis | 17/737 | 72/18723 | 1.94e-09 | 3.23e-07 | 17 |
| GO:00063647 | Cervix | HSIL_HPV | rRNA processing | 27/737 | 225/18723 | 2.67e-07 | 1.55e-05 | 27 |
| GO:001607215 | Cervix | HSIL_HPV | rRNA metabolic process | 27/737 | 236/18723 | 6.96e-07 | 3.57e-05 | 27 |
| GO:00344706 | Cervix | HSIL_HPV | ncRNA processing | 27/737 | 395/18723 | 4.01e-03 | 3.45e-02 | 27 |
| GO:000218125 | Cervix | N_HPV | cytoplasmic translation | 42/534 | 148/18723 | 2.61e-30 | 1.19e-26 | 42 |
| GO:002261325 | Cervix | N_HPV | ribonucleoprotein complex biogenesis | 30/534 | 463/18723 | 2.78e-05 | 7.49e-04 | 30 |
| GO:009730515 | Cervix | N_HPV | response to alcohol | 20/534 | 253/18723 | 4.14e-05 | 9.81e-04 | 20 |
| GO:004225424 | Cervix | N_HPV | ribosome biogenesis | 21/534 | 299/18723 | 1.46e-04 | 2.68e-03 | 21 |
| GO:000636415 | Cervix | N_HPV | rRNA processing | 14/534 | 225/18723 | 5.35e-03 | 3.84e-02 | 14 |
| GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
| GO:0022613 | Colorectum | AD | ribonucleoprotein complex biogenesis | 151/3918 | 463/18723 | 1.96e-09 | 1.39e-07 | 151 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0517145 | Cervix | N_HPV | Coronavirus disease - COVID-19 | 47/349 | 232/8465 | 1.79e-20 | 4.86e-18 | 3.80e-18 | 47 |
| hsa0301045 | Cervix | N_HPV | Ribosome | 39/349 | 167/8465 | 2.05e-19 | 2.79e-17 | 2.18e-17 | 39 |
| hsa0517155 | Cervix | N_HPV | Coronavirus disease - COVID-19 | 47/349 | 232/8465 | 1.79e-20 | 4.86e-18 | 3.80e-18 | 47 |
| hsa0301055 | Cervix | N_HPV | Ribosome | 39/349 | 167/8465 | 2.05e-19 | 2.79e-17 | 2.18e-17 | 39 |
| hsa03010 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
| hsa05171 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
| hsa030101 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
| hsa051711 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
| hsa030102 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
| hsa051712 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
| hsa030103 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
| hsa051713 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
| Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPL10A | SNV | Missense_Mutation | c.193N>C | p.Val65Leu | p.V65L | P62906 | protein_coding | tolerated(0.1) | benign(0.013) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| RPL10A | SNV | Missense_Mutation | c.519N>T | p.Lys173Asn | p.K173N | P62906 | protein_coding | tolerated(0.27) | benign(0.007) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | |
| RPL10A | SNV | Missense_Mutation | c.497N>T | p.Ala166Val | p.A166V | P62906 | protein_coding | deleterious(0.04) | possibly_damaging(0.71) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| RPL10A | deletion | Frame_Shift_Del | c.404delC | p.Pro135LeufsTer17 | p.P135Lfs*17 | P62906 | protein_coding | TCGA-AA-3692-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | folinic | PD | |||
| RPL10A | SNV | Missense_Mutation | novel | c.284A>C | p.Lys95Thr | p.K95T | P62906 | protein_coding | deleterious(0.02) | probably_damaging(0.977) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| RPL10A | SNV | Missense_Mutation | novel | c.491N>A | p.Cys164Tyr | p.C164Y | P62906 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-BG-A2L7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
| RPL10A | SNV | Missense_Mutation | c.404N>T | p.Pro135Leu | p.P135L | P62906 | protein_coding | deleterious(0.03) | possibly_damaging(0.738) | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RPL10A | SNV | Missense_Mutation | novel | c.644N>A | p.Arg215His | p.R215H | P62906 | protein_coding | tolerated(0.09) | benign(0.017) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| RPL10A | SNV | Missense_Mutation | c.292A>C | p.Lys98Gln | p.K98Q | P62906 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BC-A112-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| RPL10A | SNV | Missense_Mutation | novel | c.19N>G | p.Arg7Gly | p.R7G | P62906 | protein_coding | tolerated(0.4) | benign(0.015) | TCGA-DD-A1EE-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |